Compare Amphastar Pharmaceuticals Inc (AMPH) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Occidental Petroleum Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Occidental Petroleum Corporation trades at $53.95 (market cap $52.61B). The key difference: Occidental Petroleum Corporation is far larger — about 63.7× Amphastar Pharmaceuticals Inc's market cap, and Occidental Petroleum Corporation pays a 1.97% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | OXY | |
|---|---|---|
Market Cap | $826.08M | $52.61B |
Sector | Health | Energy |
52-Week High | $30.81 | $66.24 |
52-Week Low | $16.87 | $38.92 |
Enterprise Value | $1.22B | $73.69B |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Occidental Petroleum (OXY) trades at $52.89, up 1.13% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company shows robust profitability with a 22.42% net income margin and 14.04% ROE, though revenue has declined from $36.6B in 2022 to $21.6B in 2025. Recent news highlights rising oil prices from Middle East tensions boosting realized prices, while debt reduction and CrownRock asset integration remain focal points.
Outlook is mixed: analyst consensus is bullish with a $65.86 price target (50% buy ratings), but high P/E of 71.47 suggests premium valuation. Key opportunities include oil price leverage and carbon capture initiatives; risks involve oil volatility, debt levels, and execution under new CEO Richard Jackson. Cash flow trends show variability, with 2026 projecting positive net cash flow of $1.2B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
